☆ 4.8 Review

JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Allergy

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Chisa Nakashima et al.

Summary: Atopic dermatitis is a chronic, eczematous skin condition characterized by severe itchiness. Th2 cell-mediated immunity, skin barrier dysfunction, and pruritus contribute to the development of atopic dermatitis. The JAK/STAT pathway is involved in various inflammatory diseases, including atopic dermatitis. JAK inhibitors show promise as potential treatments for severe atopic dermatitis.

ALLERGOLOGY INTERNATIONAL (2022)

Add to Collection

Editorial Material Rheumatology

Waiting for JAK inhibitor safety data

Tue Wenzel Kragstrup et al.

Summary: This article discusses the recent addition of a 'black box warning' on Janus kinase (JAK) inhibitors used in the treatment of arthritis and other inflammatory conditions by the US FDA. The article highlights the importance of risk stratification and tailored therapy based on individual patient risk factors, proposing a simple illustration to guide clinical decision-making.

RMD OPEN (2022)

Add to Collection

Article Dermatology

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)

Thomas Bieber et al.

Summary: This study demonstrated that baricitinib combined with background topical corticosteroids can provide sustained improvements in the signs and symptoms of moderate-to-severe atopic dermatitis for up to 1 year, particularly in patients who have contraindications or inadequate response to ciclosporin A. The most common treatment-emergent adverse events with baricitinib 4 mg were nasopharyngitis, herpes simplex, influenza, and headache, and the safety profile was consistent with previous studies in patients with moderate-to-severe atopic dermatitis.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Allergy

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Jonathan Silverberg et al.

Summary: The study demonstrated that upadacitinib + TCS had long-term maintenance of efficacy and a favorable safety profile in patients with moderate-to-severe atopic dermatitis.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Review Dermatology

Janus kinase inhibitors in dermatology: Part I. A comprehensive review

Stephanie Chapman et al.

Summary: The JAK-STAT pathway is important in inflammatory dermatoses, and JAK inhibitors have shown efficacy in treating various dermatologic conditions.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Andrew Blauvelt et al.

Summary: The study demonstrated that most patients who continued abrocitinib treatment did not experience a flare during maintenance, and rescue treatment with abrocitinib plus topical therapy effectively restored response.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Vivian Y. Shi et al.

Summary: This study examines the efficacy and safety of abrocitinib among patients with moderate-to-severe atopic dermatitis who have received prior treatment with dupilumab. The results show that abrocitinib is effective in both prior dupilumab responders and nonresponders. The most common adverse events include nasopharyngitis, nausea, acne, and headache.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

Eric L. Simpson et al.

Summary: The study evaluated the long-term efficacy and safety of upadacitinib treatment in patients with atopic dermatitis over 52 weeks. Results showed that patients continuing the 15 mg and 30 mg doses maintained efficacy at week 52, with a favorable benefit-risk profile and sustained efficacy responses.

JAMA DERMATOLOGY (2022)

Add to Collection

Review Dermatology

Systemic Immunomodulatory Treatments for Atopic Dermatitis Update of a Living Systematic Review and Network Meta-analysis

Aaron M. Drucker et al.

Summary: In this study, a network meta-analysis was conducted to compare the efficacy and safety assessments of systemic treatments for atopic dermatitis. The results indicated that abrocitinib and upadacitinib had slightly higher scores than dupilumab, while upadacitinib at a daily dose of 15 mg showed similar scores to dupilumab.

JAMA DERMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Kristian Reich et al.

LANCET (2022)

Add to Collection

Review Dermatology

Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors A Systematic Review and Meta-analysis

Tai-Li Chen et al.

Summary: The systematic review and meta-analysis indicated that there is no increased risk of VTE associated with AD or treatment with JAK inhibitors based on the currently available evidence.

JAMA DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Identification of immune-related genes in atopic dermatitis, contact dermatitis, and psoriasis: A bioinformatics analysis

Lian Zhang et al.

Summary: This study aimed to identify biomarkers and therapeutic targets for atopic dermatitis (AD), contact dermatitis (CD), and psoriasis (PS). Through gene expression analysis and bioinformatics methods, we discovered immune cell infiltration, signal transduction, inflammatory response, and immune response as characteristics related to these diseases. Additionally, we identified hub genes and potential therapeutic drugs for AD, CD, and PS.

DERMATOLOGICA SINICA (2022)

Add to Collection

Review Dermatology

Recommendations on use of systemic treatments for immune-mediated dermatologic disorders in patients with confirmed COVID-19 infection: A rapid review

Chia-Ling Yu et al.

Summary: This study reviewed the latest American and European guidelines and provided recommendations for the use of systemic treatments in patients with immune-mediated dermatologic disorders and confirmed COVID-19 infection. Shared decision-making between dermatologists and patients is important in determining whether to continue Janus kinase inhibitors.

DERMATOLOGICA SINICA (2022)

Add to Collection

Article Dermatology

Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Vivian Y. Shi et al.

Summary: The study showed that Abrocitinib demonstrated high efficacy and safety in patients with moderate-to-severe atopic dermatitis, regardless of their prior response to Dupilumab.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

T. Bieber et al.

Summary: This study reports pooled safety data for baricitinib in patients with moderate-to-severe AD, confirming the established safety profile of baricitinib in this population.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Dermatology

Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

Hidemi Nakagawa et al.

Summary: The study evaluated the efficacy and safety of Delgocitinib ointment in Japanese pediatric patients with AD. Results showed significant improvement in AD in the short term and maintenance of improvement with long-term use.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Eric L. Simpson et al.

Summary: The study evaluated the efficacy and safety of baricitinib monotherapy in patients with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Results showed a higher proportion of patients achieving efficacy endpoints in the baricitinib groups at week 16.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Molecular Mechanisms of Atopic Dermatitis Pathogenesis

Jowita Sroka-Tomaszewska et al.

Summary: Atopic dermatitis is a chronic, non-infectious inflammatory skin disease with a complex pathophysiology involving genetic disorders, epidermal barrier defects, immune response alterations, and disruption of skin microbial balance. The disease significantly affects the quality of life of patients and their families, potentially requiring personalized treatment approaches.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Dermatology

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp et al.

Summary: The study evaluated the efficacy and safety of RUX cream in patients with AD, showing significant effects on reducing itch and improving skin inflammation, with superior efficacy compared to vehicle cream and good tolerability.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King et al.

Summary: The study evaluated the efficacy and safety of two Janus kinase inhibitors, Ritlecitinib and Brepocitinib, in patients with alopecia areata, showing promising results in improving hair loss. However, two patients in the Brepocitinib group experienced serious adverse events.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Thomas Bieber et al.

Summary: The study demonstrated that both 200 mg and 100 mg doses of abrocitinib showed significant efficacy in treating moderate-to-severe atopic dermatitis compared to placebo, with the 200 mg dose being superior to dupilumab in improving itch response. Neither dose of abrocitinib showed significant differences from dupilumab in most other key secondary endpoints at week 16.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Dermatology

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials

Jonathan I. Silverberg et al.

Summary: Baricitinib, a selective Janus kinase inhibitor, showed sustained long-term efficacy for patients with moderate to severe atopic dermatitis through 52 weeks of continuous therapy, improving clinical assessment scores and itch symptoms.

JAMA DERMATOLOGY (2021)

Add to Collection

Article Rheumatology

Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis

Mark Yates et al.

Summary: A meta-analysis of RCT data on JAK inhibitors in IMID patients found a low risk of VTE, not supporting current warnings. These findings will help in the continued development of clinical guidelines for the use of JAK inhibitors in IMIDs.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Review Cell Biology

The PI3K/Akt Pathway: Emerging Roles in Skin Homeostasis and a Group of Non-Malignant Skin Disorders

Yan Teng et al.

Summary: The PI3K/Akt signaling pathway plays a crucial role in the regulation of cell proliferation, differentiation, and migration, as well as in skin development and homeostasis. Dysregulation of this pathway is linked to various human cutaneous malignancies and non-malignant skin disorders. Understanding the dysfunction of the PI3K/Akt pathway has led to advancements in identifying therapeutic targets for non-malignant skin disorders.

CELLS (2021)

Add to Collection

Article Dermatology

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

Kristin J. Meyers et al.

Summary: This study found that the risk of venous thromboembolism (VTE) is low among patients with atopic dermatitis (AD), and AD is not an independent risk factor for VTE. While the risk of VTE was slightly higher in patients with moderate-to-severe AD compared to non-AD controls, this difference disappeared after adjustments for healthcare use and VTE risk factors.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Dermatology

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L. Simpson et al.

Summary: Abrocitinib has been shown to be an effective treatment for atopic dermatitis with a manageable tolerability and safety profile for long-term use, especially when proper patient and dose selection are utilized. The study results suggest that abrocitinib can be used as a long-term therapy for moderate-to-severe atopic dermatitis.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

Yan Zhao et al.

Summary: Oral SHR0302 demonstrated effectiveness and good tolerance in Chinese adult patients with moderate to severe atopic dermatitis, leading to improved disease assessment response rate and Eczema Area and Severity Index. However, mild treatment-emergent adverse events were reported in some patients.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

Silvio Danese et al.

Summary: This review highlights the role of TYK2 signaling in the pathogenesis of inflammatory bowel disease (IBD), the selective inhibition of TYK2 and the potential clinical implications of TYK2 inhibition. While Pan-JAK inhibitors have inconsistent efficacy and toxicities, selective TYK2 inhibitors may offer a more targeted and potentially safer approach in the management of IBD and other immune-mediated inflammatory diseases. Future studies will be crucial in determining the role of selective, allosteric TYK2 inhibition in the management of IBD.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Dermatology

Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis

Lu Zhang et al.

Summary: This study compared the efficacy and safety of topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD) treatment. The results showed that these inhibitors had higher IGA response compared to placebo and demonstrated a comparable safety profile.

JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich et al.

Summary: This study evaluated the efficacy and safety of upadacitinib in combination with topical corticosteroids for moderate-to-severe atopic dermatitis, showing that upadacitinib was more effective and well tolerated compared to placebo.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials

Emma Guttman-Yassky et al.

Summary: The clinical trials demonstrated that Upadacitinib may be an effective treatment option for moderate-to-severe atopic dermatitis, with a significant improvement in symptoms for most patients within 16 weeks, and both dosages were well tolerated.

LANCET (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial

Lawrence F. Eichenfield et al.

Summary: The study found that oral abrocitinib combined with topical therapy was significantly more effective than placebo with topical therapy in adolescents with moderate-to-severe AD, with an acceptable safety profile.

JAMA DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial

Andrew Blauvelt et al.

Summary: This study compared the safety and efficacy of upadacitinib vs dupilumab in patients with moderate-to-severe atopic dermatitis, with the results showing superior efficacy of upadacitinib at week 16 compared to dupilumab, with no new safety signals identified.

JAMA DERMATOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Michelle Le et al.

Summary: Oral JAK inhibitors have shown significant clinical efficacy and reassuring safety profile in the treatment of moderate-to-severe atopic dermatitis, providing rapid symptom control and serving as a reliable systemic treatment option for patients unresponsive to topical treatments.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Review Dermatology

Taiwan dermatological association recommendations for coronavirus disease of 2019 vaccination in patients treated with immunotherapeutics

Chih-Hung Lee et al.

Summary: The article presents considerations for COVID-19 vaccination in patients on immunotherapeutics for immune-mediated dermatological diseases and summarizes recommendations relevant to clinical practice in Taiwan. These dynamic recommendations from the Taiwan Dermatological Association serve as an interim guide to optimize patient care. The evolving clinical practice is expected to be informed by new evidence emerging in the pandemic.

DERMATOLOGICA SINICA (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The JAK/STAT signaling pathway: from bench to clinic

Xiaoyi Hu et al.

Summary: The JAK/STAT signaling pathway is a crucial cellular signal transduction pathway, associated with various cancers and autoimmune diseases. Researchers discussed the composition, activation, and regulation of this pathway, as well as its role in diseases.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Allergy

Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis

Thomas Bieber

ALLERGY (2020)

Add to Collection

Review Allergy

Mechanisms of Dupilumab

Hani Harb et al.

CLINICAL AND EXPERIMENTAL ALLERGY (2020)

Add to Collection

Article Allergy

Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream

Brian S. Kim et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Allergy

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Emma Guttman-Yassky et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Dermatology

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

E. L. Simpson et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Role of Th17-Related Cytokines in Atopic Dermatitis

Makoto Sugaya

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Letter Dermatology

Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model

Yasuo Yamamoto et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2020)

Add to Collection

Article Dermatology

Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

Hidemi Nakagawa et al.

JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Hidemi Nakagawa et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Delgocitinib: First Approval

Sohita Dhillon

DRUGS (2020)

Add to Collection

Article Dermatology

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

Seth B. Forman et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial

Jonathan Silverberg et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L Simpson et al.

LANCET (2020)

Add to Collection

Article Dermatology

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial

Kristian Reich et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Article Dermatology

16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial

Stacy Smith et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Immunology

The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside

Taoming Liu et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4-JAK-STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis

Masutaka Furue

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Review Dermatology

Association of atopic dermatitis with inflammatory bowel disease: A systematic review and meta-analysis

Chi-Hui Wang et al.

DERMATOLOGICA SINICA (2020)

Add to Collection

Article Medicine, General & Internal

Atopic dermatitis: Tofacitinib, an option for refractory disease

Sineida Berbert Ferreira et al.

CLINICAL CASE REPORTS (2020)

Add to Collection

Article Dermatology

A study on the knowledge, attitudes, and practices of Asian dermatologists in the management of atopic dermatitis

Siqing Ee et al.

DERMATOLOGICA SINICA (2020)

Add to Collection

Article Dermatology

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Emma Guttman-Yassky et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Allergy

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

Patrick M. Brunner et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Article Rheumatology

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Katie Bechman et al.

RHEUMATOLOGY (2019)

Add to Collection

Article Allergy

Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis

Ana B. Pavel et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Review Immunology

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease

David Bastian et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Allergy

Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis

Hidemi Nakagawa et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Article Dermatology

JAK Inhibitors for Atopic Dermatitis: An Update

Helen He et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial

Melinda J. Gooderham et al.

JAMA DERMATOLOGY (2019)

Add to Collection

Review Immunology

JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation

Dagmar Gotthardt et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Chronic inflammation in the etiology of disease across the life span

David Furman et al.

NATURE MEDICINE (2019)

Add to Collection

Review Medicine, Research & Experimental

The impact of lifestyle factors on evolution of atopic dermatitis: An alternative approach

Iulia Solomon et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)

Add to Collection

Review Physiology

Interleukin-5 in the Pathophysiology of Severe Asthma

Corrado Pelaia et al.

FRONTIERS IN PHYSIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study

Alexis Ogdie et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Review Allergy

JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease

Michael D. Howell et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)

Add to Collection

Article Dermatology

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study

H. Nakagawa et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Review Dermatology

Dupilumab: A review of its use in the treatment of atopic dermatitis

Melinda J. Gooderham et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Add to Collection

Review Cell Biology

IL-33/IL-31 Axis: A Potential Inflammatory Pathway

Eleonora Di Salvo et al.

MEDIATORS OF INFLAMMATION (2018)

Add to Collection

Article Anesthesiology

Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain

Louise S. C. Nicol et al.

PAIN (2018)

Add to Collection

Review Biochemistry & Molecular Biology

The molecular details of cytokine signaling via the JAK/STAT pathway

Rhiannon Morris et al.

PROTEIN SCIENCE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic Targets

Jolanta Klonowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Article Allergy

Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide

J. P. Thyssen et al.

ALLERGY (2018)

Add to Collection

Article Allergy

Itch in Atopic Dermatitis

Makiko Kido-Nakahara et al.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2017)

Add to Collection

Review Allergy

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

Patrick M. Brunner et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Add to Collection

Review Dermatology

JAK inhibitors in dermatology: The promise of a new drug class

William Damsky et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Add to Collection

Article Cell Biology

Inhibition of JAK/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis

Zhaohui Shi et al.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Daniella M. Schwartz et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

Add to Collection

Review Chemistry, Medicinal

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Corrado Pelaia et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2017)

Add to Collection

Article Cell Biology

Genome-wide Analysis of STAT3-Mediated Transcription during Early Human Th17 Cell Differentiation

Subhash K. Tripathi et al.

CELL REPORTS (2017)

Add to Collection

Review Immunology

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus

Pawinee Rerknimitr et al.

INFLAMMATION AND REGENERATION (2017)

Add to Collection

Review Allergy

Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Nicholas K. Mollanazar et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Targeting key proximal drivers of type 2 inflammation in disease

Namita A. Gandhi et al.

NATURE REVIEWS DRUG DISCOVERY (2016)

Add to Collection

Article Dermatology

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

R. Bissonnette et al.

BRITISH JOURNAL OF DERMATOLOGY (2016)

Add to Collection

Article Allergy

The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves

Micha Feld et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Article Medicine, Research & Experimental

Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis

Takuwa Yasuda et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

E. L. Simpson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Immunology

Interleukin-22: Immunobiology and Pathology

Jarrod A. Dudakov et al.

ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)

Add to Collection

Article Allergy

Pathogenesis of atopic dermatitis

W. Peng et al.

CLINICAL AND EXPERIMENTAL ALLERGY (2015)

Add to Collection

Article Allergy

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling

Wataru Amano et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)

Add to Collection

Article Dermatology

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

Lauren L. Levy et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch

Miho Shiratori-Hayashi et al.

NATURE MEDICINE (2015)

Add to Collection

Article Allergy

Th17 cells and tissue remodeling in atopic and contact dermatitis

D. Simon et al.

ALLERGY (2014)

Add to Collection

Review Biochemistry & Molecular Biology

The molecular regulation of Janus kinase (JAK) activation

Jeffrey J. Babon et al.

BIOCHEMICAL JOURNAL (2014)

Add to Collection

Review Allergy

Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches

Donald Y. M. Leung et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Allergy

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

Jennifer D. Hamilton et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Allergy

A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1

Ferda Cevikbas et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Dermatology

Interferon-γ Decreases Ceramides with Long-Chain Fatty Acids: Possible Involvement in Atopic Dermatitis and Psoriasis

Chisato Tawada et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease

H. Yuhara et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Review Multidisciplinary Sciences

Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990-2010: A Systematic Review of Epidemiological Studies

Ivette A. G. Deckers et al.

PLOS ONE (2012)

Add to Collection

Article Clinical Neurology

Interleukin-17 Contributes to Neuroinflammation and Neuropathic Pain Following Peripheral Nerve Injury in Mice

Cristina Fabiola Kim et al.

JOURNAL OF PAIN (2011)

Add to Collection

Review Clinical Neurology

Role of TNF-alpha during central sensitization in preclinical studies

Pablo Andrade et al.

NEUROLOGICAL SCIENCES (2011)

Add to Collection

Article Immunology

Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis

Lydia Durant et al.

IMMUNITY (2010)

Add to Collection

Article Multidisciplinary Sciences

Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling

Yrina Rochman et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection

Review Dermatology

Atopic Dermatitis: A Disease Caused by Innate Immune Defects?

Anna De Benedetto et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)

Add to Collection

Review Immunology

Structure and signalling in the IL-17 receptor family

Sarah L. Gaffen

NATURE REVIEWS IMMUNOLOGY (2009)

Add to Collection

Review Biochemistry & Molecular Biology

Structures and biological functions of IL-31 and IL-31 receptors

Qing Zhang et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2008)

Add to Collection

Article Dermatology

Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

Chizuko Koga et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)

Add to Collection

Review Medicine, General & Internal

Mechanisms of disease: Atopic dermatitis

Thomas Bieber

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Review Cell Biology

Inteferons pen the JAK-STAT pathway

Christian Schindler et al.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)

Add to Collection

Article Allergy

IL-31: A new link between T cells and pruritus in atopic skin inflammation

E Sonkoly et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)

Add to Collection

Article Biochemistry & Molecular Biology

Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line - Pathways that are shared with and distinct from IL-10

D Lejeune et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)

Add to Collection

Review Allergy

Bacterial infections and atopic dermatitis

K Breuer et al.

ALLERGY (2001)

Add to Collection

Article Immunology

Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin

A Pandey et al.

NATURE IMMUNOLOGY (2000)

Add to Collection

Article Allergy

IL-4/IL-13 signaling beyond JAK/STAT

H Jiang et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.